Compounded GLP-1 Medications: What Happened and What's Available Now

Few topics in telehealth have generated more confusion — and more urgent patient questions — than the evolving story of compounded GLP-1 medications. If you've been following semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound) news over the past few years, you've likely seen headlines swinging from "shortages create compounding boom" to "FDA cracks down on compounded GLP-1s." The truth, as usual, is more nuanced.

This article covers the complete timeline: how the shortage started, why compounding was permitted, what changed when the shortage ended, where things stand in 2026, and how to navigate your options legally and safely.

The GLP-1 Shortage: How It Started

The story begins in earnest around 2022, when semaglutide exploded from a niche diabetes medication into a mainstream weight-loss phenomenon. Ozempic had been approved for type 2 diabetes since 2017, but its weight-loss effects were becoming widely known. In 2021, the FDA approved Wegovy (higher-dose semaglutide) specifically for chronic weight management, and demand surged dramatically.

Novo Nordisk, the manufacturer, simply could not produce enough supply to meet demand. By mid-2022, both Ozempic and Wegovy were placed on the FDA's Drug Shortage List — an official designation that carries significant regulatory implications. Tirzepatide (Mounjaro, Zepbound) followed a similar trajectory as its weight-loss applications became apparent, landing on the shortage list as well.

The shortage was real, documented, and affected hundreds of thousands of patients who either couldn't fill their prescriptions or faced months-long waits.

Why Compounding Was Allowed During the Shortage

Here's where federal law becomes important. Under the Federal Food, Drug, and Cosmetic Act (FDCA), when a drug appears on the FDA's official shortage list, licensed compounding pharmacies gain special legal permission to produce copies of that drug — even if it contains an active pharmaceutical ingredient that would otherwise be restricted from compounding.

This is a deliberate policy safety valve designed to help patients maintain access to medically necessary drugs when commercial supply fails. During a shortage, compounding pharmacies can legally produce semaglutide-containing medications for patients with valid prescriptions from licensed providers.

503A vs. 503B Pharmacies: The Critical Distinction

Not all compounding pharmacies are equal under the law. There are two legally distinct types:

• 503A pharmacies (traditional compounding pharmacies) compound medications for individual patients based on specific prescriptions from licensed practitioners. They must comply with USP standards and state pharmacy board oversight. They can produce compounds for specific named patients but not large batches for general sale.
• 503B outsourcing facilities are FDA-registered facilities that operate under stricter federal oversight — more like small drug manufacturers. They can produce larger batches of compounded drugs without patient-specific prescriptions and are subject to current Good Manufacturing Practice (cGMP) requirements. 503B facilities provide higher quality assurance and are generally considered safer for compounded injectables.

During the shortage period, both 503A and 503B facilities were producing compounded semaglutide. Quality varied widely. Reputable 503B facilities with rigorous quality controls produced products that thousands of patients used safely. Some 503A pharmacies with less oversight produced products of more variable quality. And unfortunately, some companies attempted to sell "semaglutide" products with minimal or no real pharmaceutical oversight at all.

What Changed When the Shortage Ended

In late 2024 and into 2025, the FDA made the determination that semaglutide (specifically the forms used in Ozempic and Wegovy) was no longer in shortage. Tirzepatide (Mounjaro/Zepbound) reached similar status around the same timeframe.

This status change has cascading regulatory consequences:

• The statutory basis that permitted compounding pharmacies to copy branded semaglutide and tirzepatide expired with the end of the shortage designation
• The FDA issued guidance making clear that 503B outsourcing facilities could no longer produce large-batch compounded semaglutide once the shortage ended
• 503A pharmacies faced similar restrictions — compounding copies of commercially available drugs for reasons other than a documented clinical need (like an allergy to an inactive ingredient or a dose not commercially available) became legally problematic
• The FDA began enforcement action against compounders continuing to produce semaglutide copies without legal justification

This created significant disruption in the telehealth and compounding pharmacy ecosystem. Many companies that had built their entire business model around compounded semaglutide had to pivot, shut down, or face legal risk.

The 2025–2026 Legal Landscape

As of 2026, the situation has stabilized somewhat — but it remains complex. Here's where things stand:

Compounded Semaglutide

Large-batch compounding of semaglutide copies by 503B facilities is no longer permissible under FDA regulations now that the shortage has been resolved. However, compounding for individual patients with specific clinical needs remains a gray area. A 503A pharmacy may legally compound a semaglutide preparation if:

• A patient has a documented allergy to an inactive ingredient in the commercial product
• A dose strength is medically necessary that isn't commercially available
• The prescription comes from a licensed practitioner with a legitimate patient-specific need

The FDA has been clear that compounding simply to offer a lower-cost alternative to Ozempic or Wegovy — without a specific clinical justification — is not permitted. Enforcement has been increasing, and companies openly advertising "compounded semaglutide" as an Ozempic alternative should be viewed with significant skepticism.

Compounded Tirzepatide

Tirzepatide's situation is somewhat more nuanced. Legal challenges and ongoing FDA review processes have created a more contested landscape. Some 503B facilities are still producing compounded tirzepatide pending the resolution of legal disputes. This is an area of active regulatory flux, and patients should seek up-to-date guidance from their provider.

What's Clearly Available in 2026

The cleanest options for patients seeking GLP-1 treatment in 2026 are:

• Brand-name Ozempic (semaglutide 0.5–2 mg weekly) — FDA-approved for type 2 diabetes; widely available; often covered by insurance for diabetes indication
• Brand-name Wegovy (semaglutide 2.4 mg weekly) — FDA-approved for chronic weight management; insurance coverage improving; manufacturer savings programs available
• Brand-name Mounjaro (tirzepatide) — FDA-approved for type 2 diabetes
• Brand-name Zepbound (tirzepatide) — FDA-approved for chronic weight management; rapidly growing availability

Brand-name products are manufactured under strict quality standards, have well-established safety profiles, and come with patient support programs. They're also significantly more expensive than compounded alternatives were — which is a real barrier for patients without insurance coverage.

How to Find Legitimate Treatment: What to Look For

If you're navigating GLP-1 options, here's how to protect yourself:

Red Flags to Avoid

• "Semaglutide" sold without a prescription — This is illegal. Period. Any company selling semaglutide or tirzepatide without a valid prescription from a licensed provider is operating outside the law.
• Prices dramatically lower than anything else — Legitimate pharmaceutical-grade compounds cost real money to produce. If something sounds too cheap to be real, it probably is.
• No licensed provider involvement — GLP-1 medications require medical supervision. If a company is skipping this step, that's a serious warning sign.
• Claims of "FDA-approved compounded semaglutide" — FDA doesn't approve compounded drugs. This phrasing is misleading by definition.
• No verifiable pharmacy license — Legitimate compounding pharmacies are licensed by state boards and, for 503B facilities, registered with the FDA. You can verify this.

What Legitimate Providers Do

• Conduct a real medical consultation before prescribing
• Review your health history and labs
• Work with licensed, verifiable pharmacies
• Monitor your progress and adjust your treatment
• Explain your options honestly, including brand-name products
• Stay current with FDA guidance and adjust their offerings accordingly

How Truventa Navigates This Landscape

At Truventa Medical, our approach is built around working with licensed healthcare providers and pharmacies that operate within current FDA and state regulatory frameworks. We stay current with evolving guidance and are transparent with patients about what's legally available at any given time.

We believe that patients deserve honest, up-to-date information — not marketing spin designed to obscure regulatory reality. Our providers will discuss your specific clinical situation, your insurance options, manufacturer savings programs, and what GLP-1 treatment pathway makes the most sense for you legally, safely, and affordably.

The GLP-1 landscape is complex, but that doesn't mean your path to treatment has to be. Working with a knowledgeable provider is the best way to navigate it.